Sebastian Weiterer

Sebastian Weiterer

Auto-generated profile, based on publicly available information

Sebastian Weiterer

Department of Anaesthesiology, Heidelberg University Hospital, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 February 2016 in Critical Care
Verified
Journal Article
Open access
PDF file
CAC. Arens
C. Arens
SBS. A. Bajwa
S. A. Bajwa
Christian KochChristian Koch
Christian Koch
BSBenedikt Siegler
Benedikt Siegler
Emmanuel SchneckEmmanuel Schneck
Emmanuel Schneck
FUFlorian Uhle
Florian Uhle
Long-lasting impairment of the immune system is believed to be the underlying reason for delayed deaths after surviving sepsis. We tested the hypothesis of persisting changes to the immune system in survivors of sepsis for the first time. In our prospective, cross-sectional pilot study, eight former patients who survived catecholamine-dependent sepsis and eight control individuals matched for age, sex, diabetes and renal insufficiency were enrolled. Each participant completed a questionnaire concerning morbidities, medications and infection history. Peripheral blood was collected for determination of i) immune cell subsets (CD4+, CD8+ T cells; CD25+ CD127- regulatory T cells; CD14+ monocytes), ii) cell surface receptor expression (PD-1, BTLA, TLR2, TLR4, TLR5, Dectin-1, PD-1 L), iii) HLA-DR expression, and iv) cytokine secretion (IL-6, IL10, TNF-α, IFN-γ) of whole blood stimulated with either α-CD3/28, LPS or zymosan. After surviving sepsis, former patients presented with increased numbers of clinical apparent infections, including those typically associated with an impaired immune system. Standard inflammatory markers indicated a low-level inflammatory situation in former sepsis patients. CD8+ cell surface receptor as well as monocytic HLA-DR density measurements showed no major differences between the groups, while CD4+ T cells tended towards two opposed mechanisms of negative immune cell regulation via PD-1 and BTLA. Moreover, the post-sepsis group showed alterations in monocyte surface expression of distinct pattern recognition receptors; most pronouncedly seen in a decrease of TLR5 expression. Cytokine secretion in response to important activators of both the innate (LPS, zymosan) and the adaptive immune system (α-CD3/28) seemed to be weakened in former septic patients. Cytokine secretion as a reaction to different activators of the immune system seemed to be comprehensively impaired in survivors of sepsis. Among others, this could be based on trends in the downregulation of distinct cell surface receptors. Based on our results, the conduct of larger validation studies seems feasible, aiming to characterize alterations and to find potential therapeutic targets to engage.

20 March 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SWSebastian Weiterer
Sebastian Weiterer
FUFlorian Uhle
Florian Uhle
CLChristoph Lichtenstern
Christoph Lichtenstern
BSBenedikt H. Siegler
Benedikt H. Siegler
SBSabin Bhuju
Sabin Bhuju
MWMarkus A. Weigand
Markus A. Weigand
Sepsis is a global burden and the primary cause of death in intensive care units worldwide. The pathophysiological changes induced by the host’s systemic inflammatory response to infection are not yet fully understood. During sepsis, the immune system is confronted with a variety of factors, which are integrated within the individual cells and result in changes of their basal state of responsiveness. Epigenetic mechanisms like histone modifications are known to participate in the control of immune reactions, but so far the situation during sepsis is unknown. In a pilot approach, we performed combined chromatin immunoprecipitation followed by high-throughput sequencing to assess the genome-wide distribution of the chromatin modifications histone 3 lysine 4 and 27 trimethylation and lysine 9 acetylation in monocytes isolated from healthy donors (n = 4) and patients with sepsis (n = 2). Despite different underlying causes for sepsis, a comparison over promoter regions shows a high correlation between the patients for all chromatin marks. These findings hold true also when comparing patients to healthy controls. Despite the global similarity, differential analysis reveals a set of distinct promoters with significant enrichment or depletion of histone marks. Further analysis of overrepresented GO terms show an enrichment of genes involved in immune function. To the most prominent ones belong different members of the HLA family located within the MHC cluster together with the gene coding for the major regulator of this locus—CIITA. We are able to show for the first time that sepsis in humans induces selective and precise changes of chromatin modifications in distinct promoter regions of immunologically relevant genes, shedding light on basal regulatory mechanisms that might be contributing to the functional changes occurring in monocytes.

3 May 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BSBenedikt Siegler
Benedikt Siegler
MAMarc Altvater
Marc Altvater
JTJan Niklas Thon
Jan Niklas Thon
CNChristopher Neuhaus
Christopher Neuhaus
CAChristoph Arens
Christoph Arens
SWSebastian Weiterer
Sebastian Weiterer
Background: Postoperative abdominal infections belong to the most common triggers of sepsis and septic shock in intensive care units worldwide. While monocytes play a central role in mediating the initial host response to infections, sepsis-induced immune dysregulation is characterized by a defective antigen presentation to T-cells via loss of Major Histocompatibility Complex Class II DR (HLA-DR) surface expression. Here, we hypothesized a sepsis-induced differential occupancy of the CCCTC-Binding Factor (CTCF), an architectural protein and superordinate regulator of transcription, inside the Major Histocompatibility Complex Class II (MHC-II) region in patients with postoperative sepsis, contributing to an altered monocytic transcriptional response during critical illness. Results: Compared to a matched surgical control cohort, postoperative sepsis was associated with selective and enduring increase in CTCF binding within the MHC-II. In detail, increased CTCF binding was detected at four sites adjacent to classical HLA class II genes coding for proteins expressed on monocyte surface. Gene expression analysis revealed a sepsis-associated decreased transcription of (i) the classical HLA genes HLA-DRA, HLA-DRB1, HLA-DPA1 and HLA-DPB1 and (ii) the gene of the MHC-II master regulator, CIITA (Class II Major Histocompatibility Complex Transactivator). Increased CTCF binding persisted in all sepsis patients, while transcriptional recovery CIITA was exclusively found in long-term survivors. Conclusion: Our experiments demonstrate differential and persisting alterations of CTCF occupancy within the MHC-II, accompanied by selective changes in the expression of spatially related HLA class II genes, indicating an important role of CTCF in modulating the transcriptional response of immunocompromised human monocytes during critical illness.

13 September 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BSBenedikt Siegler
Benedikt Siegler
FUFlorian Uhle
Florian Uhle
CLChristoph Lichtenstern
Christoph Lichtenstern
CAChristoph Arens
Christoph Arens
MBMarek Bartkuhn
Marek Bartkuhn
SWSebastian Weiterer
Sebastian Weiterer
Antigen presentation on monocyte surface to T-cells by Major Histocompatibility Complex, Class II (MHC-II) molecules is fundamental for pathogen recognition and efficient host response. Accordingly, loss of Major Histocompatibility Complex, Class II, DR (HLA-DR) surface expression indicates impaired monocyte functionality in patients suffering from sepsis-induced immunosuppression. Besides the impact of Class II Major Histocompatibility Complex Transactivator (CIITA) on MHC-II gene expression, X box-like (XL) sequences have been proposed as further regulatory elements. These elements are bound by the DNA-binding protein CCCTC-Binding Factor (CTCF), a superordinate modulator of gene transcription. Here, we hypothesized a differential interaction of CTCF with the MHC-II locus contributing to an altered monocyte response in immunocompromised septic patients. We collected blood from six patients diagnosed with sepsis and six healthy controls. Flow cytometric analysis was used to identify sepsis-induced immune suppression, while inflammatory cytokine levels in blood were determined via ELISA. Isolation of CD14++ CD16—monocytes was followed by (i) RNA extraction for gene expression analysis and (ii) chromatin immunoprecipitation to assess the distribution of CTCF and chromatin modifications in selected MHC-II regions. Compared to healthy controls, CD14++ CD16—monocytes from septic patients with immune suppression displayed an increased binding of CTCF within the MHC-II locus combined with decreased transcription of CIITA gene. In detail, enhanced CTCF enrichment was detected on the intergenic sequence XL9 separating two subregions coding for MHC-II genes. Depending on the relative localisation to XL9, gene expression of both regions was differentially affected in patients with sepsis. Our experiments demonstrate for the first time that differential CTCF binding at XL9 is accompanied by uncoupled MHC-II expression as well as transcriptional and epigenetic alterations of the MHC-II regulator CIITA in septic patients. Overall, our findings indicate a sepsis-induced enhancer blockade mediated by variation of CTCF at the intergenic sequence XL9 in altered monocytes during immunosuppression.

13 August 2012 in Intensivmedizin up2date
Verified
Journal Article
Closed access
PDF file
SWSebastian Weiterer
Sebastian Weiterer
BTBirgit Trierweiler-Hauke
Birgit Trierweiler-Hauke
AHAndreas Hecker
Andreas Hecker
GSGabor Szalay
Gabor Szalay
MHMartin Heinrich
Martin Heinrich
MWMarkus A. Weigand
Markus A. Weigand
Die Entwicklung einer generalisierten Muskelschwäche und die damit einhergehenden Funktionseinschränkungen sind ein essenzielles Problem von Intensivpatienten. Inaktivität, entzündliche Prozesse (Sepsis, ARDS) und auch Medikamente sind die wichtigsten Ursachen muskulärer Schwächen bei Intensivpatienten. Die Entstehung der Critical-illness-Myopathie und -Polyneuropathie ist komplex und beinhaltet metabolische, inflammatorische und bioenergetische Veränderungen. Für den Genesungsprozess und zur Wiederherstellung des funktionellen Status ist eine an den Zustand des Patienten angepasste Mobilisierung von großer Bedeutung. Zur frühzeitigen Erkennung einer Muskelschwäche eignet sich die Handgriff-Dynamometrie als einfacheres objektives Mittel zur Messung der Handgriffstärke, welche Rückschlüsse auf die globale Kraft erlaubt. Auch bei beatmeten Patienten kann die Frühmobilisierung neuromuskulären Komplikationen vorbeugen. Um bei beatmeten Patienten die Belastung angepasst zu dosieren, sind neurophysiologische Tests wie die Elektromyografie und eine klinische Verlaufsbeobachtung (MRD-Score) hilfreich. Bei Eingriffen an Oberbauchorganen muss man mit einem sympathischen Pleuraergusses rechnen. Eine intensive Mobilisierung erlaubt es, postoperative pulmonale Komplikationen nach Oberbaucheingriffen zu vermeiden. Die Möglichkeiten der Mobilisierung unfallchirurgischer Intensivpatienten hängt von der Art und dem Ausmaß der Verletzungen sowie der Stabilität der Osteosynthesen ab. Doch auch die individuellen Möglichkeiten des Patienten und dessen Begleiterkrankungen nehmen Einfluss auf seine Mobilisierung. Der Einsatz von Medikamenten zur Therapie der Folgen einer längerfristigen Immobilisierung bedarf einer individuellen Nutzen-Risiko-Abwägung. Die elektrische Muskelstimulation ist eine Methode mit viel Potenzial und eine gut tolerierte Methode zur Prävention der Muskelatrophie.

1 October 2014 in Journal of Trauma and Acute Care Surgery
Verified
Journal Article
Closed access
FUFlorian Uhle
Florian Uhle
DNDenise van Den Nouland
Denise van Den Nouland
SLSimon Little
Simon Little
TMThilo Menges
Thilo Menges
SWSebastian Weiterer
Sebastian Weiterer
CLChristoph Lichtenstern
Christoph Lichtenstern
Life-threatening traumatic injuries lead to a complex inflammation-driven pathophysiology. Receptor of advanced glycation end product (RAGE) is a multiligand receptor of several endogenous alarmins, while cytokeratin 18 is a structural component of the filament of epithelial cells. Both proteins can be frequently found in plasma of patients with different diseases, whereby they have distinct underlying mechanism of formation. In this prospective observational study, we wanted to shed light on the kinetic of plasmatic RAGE and cytokeratin 18 isoforms after severe trauma, thereby also addressing the association of these markers with inflammation and their potential use as biomarkers. Plasma samples of 77 patients with severe multiple trauma as defined by an Injury Severity Score (ISS) 16 or greater were obtained from a local repository and levels of soluble RAGE, endogenous secretory RAGE, cytokeratin 18, cleaved cytokeratin 18, and interleukin 6 by enzyme-linked immunosorbent assay. Demographic and routine parameters of the cohort were extracted from an electronic patient data management system. Both RAGE isoforms were transiently increased in plasma within 24 hours after trauma, while cytokeratin 18 levels were unchanged. Moreover, soluble RAGE concentrations in patients with thoracic injuries were higher compared with patients without injury, and both isoforms of RAGE discriminated between patients with most severe adult respiratory distress syndrome and patients with milder forms. In addition, cleaved and total cytokeratin 18 levels differ between patients with hepatic dysfunction and normal function, without possessing discriminatory power. RAGE and cytokeratin 18 isoforms correlated significantly but to a low extent with interleukin 6, while the isoforms of both parameters correlated to a high extent with one another. The release of RAGE (but not cytokeratin 18) isoforms occurs early and transiently after trauma and is associated with the extent of injury and inflammatory response. RAGE and cytokeratin 18 isoforms have the potential to act as diagnostic or prognostic biomarkers of lung and hepatic dysfunction. Epidemiologic/prognostic study, level IV.